Contact this trialFirst, we need to learn more about you.
R3R01 for Alport Syndrome
Recruiting1 awardPhase 2
Dallas, Texas
This trial tests R3R01, a new drug that lowers fat in kidney cells to improve kidney function and reduce damage. It targets patients with Alport Syndrome and steroid-resistant FSGS who have high protein levels in their urine because their conditions are not improving with current treatments. Another drug has shown promise in reducing protein levels and kidney damage in animal studies.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.